Fixed dose drug combinations – are they pharmacoeconomically sound?:

Simple item page
dc.contributor.authorGodmana, Brian
dc.contributor.authorMcCabee, Holly
dc.contributor.authorLeong, Trudy D.
dc.contributor.authorMueller, Debjani
dc.contributor.authorMartini, Antony P.
dc.contributor.authorHoxhak, Iris
dc.contributor.authorMwital, Julius C.
dc.contributor.authorMutashambara Rwegereram, Godfrey
dc.contributor.authorMasselen, Amos
dc.contributor.authorCostao, Juliana de Oliveira
dc.contributor.authorRezende Macedo do Nascimentoa, Renata Cristina
dc.contributor.authorPires de Lemoso, Livia Lovato
dc.contributor.authorTachkovs, Konstantin
dc.contributor.authorMilushewas, Petya
dc.contributor.authorPatrickt, Okwen
dc.contributor.authorLum Nibat, Loveline
dc.contributor.authorLaiusw, Ott
dc.contributor.authorSefah, Israel
dc.contributor.authorAbdulsalimy, Suhaj
dc.contributor.authorSoleymaniz, Fatemeh
dc.contributor.authorGuantai, Anastasia N
dc.contributor.authorAchieng, Loice
dc.contributor.authorOluka, Margaret
dc.contributor.authorJakupi, Arianit
dc.contributor.authorLogviss, Konstantīns
dc.contributor.authorHassali, Mohamed Azmi
dc.contributor.authorKibuule, Dan
dc.contributor.authorKalemeera, Francis
dc.contributor.authorMubita, Mwangana
dc.contributor.authorFadaregg, Joseph
dc.contributor.authorOgunleye, Olayinka O.
dc.contributor.authorSaleem, Zikria
dc.contributor.authorHussain, Shazhad
dc.contributor.authorBochenek, Tomasz
dc.contributor.authorMardare, Ileana
dc.contributor.authorAlrasheedy, Alian A.
dc.contributor.authorFurst, Jurij
dc.contributor.authorTomek, Dominik
dc.contributor.authorMarkovic-Pekovic, Vanda
dc.contributor.authorRampamba, Enos M.
dc.contributor.authorAlfadl, Abubakr
dc.contributor.authorAmu, Adefolarin A.
dc.contributor.authorMatsebula, Zinhle
dc.contributor.authorThi Phuong, Thuy Nguyen
dc.contributor.authorThanh, Binh Nguyen
dc.contributor.authorKalungia, Aubrey Chichonyi
dc.contributor.authorZaranyika, Trust
dc.contributor.authorMasuka, Nyasha
dc.contributor.authorOlarua, Ioana D.
dc.contributor.authorWale, Janney
dc.contributor.authorHill, Ruaraidh
dc.contributor.authorKurdia, Amanj
dc.contributor.authorTimoneya, Angela
dc.contributor.authorCampbell, Stephen
dc.contributor.authorMeyer, Johanna C.
dc.date.accessioned2023-08-23T10:44:49Z
dc.date.available2023-08-23T10:44:49Z
dc.date.issued2020
dc.descriptionResearch article
dc.description.abstractIntroduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed. KEYWORDS: Fixed dose combinations; pharmacoeconomics; adherence; medicines; noncommunicable diseases; infectious diseases; lower and middle income countries
dc.description.sponsorshipUniversity of Strathclyde, University of Manchester, Manchester, Busitema University
dc.identifier.citationGodmana, B. . . . et al. (2020). Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcomes Research, 20:1, 1-26, DOI: 10.1080/14737167.2020.1734456
dc.identifier.urihttps://doi.org/10.60682/y1y8-j990
dc.language.isoen
dc.publisherInforma UK Limited
dc.subjectResearch Subject Categories::MEDICINE::Physiology and pharmacology::Pharmacological research::Pharmacology
dc.subjectResearch Subject Categories::MEDICINE::Microbiology, immunology, infectious diseases::Infectious diseases
dc.titleFixed dose drug combinations – are they pharmacoeconomically sound?:
dc.title.alternativeFindings and implications especially for lower- and middleincome countries
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Fixed-dose-drug-combinations-are-they-pharmacoeconomically-sound-2020
Size:
5.79 MB
Format:
Adobe Portable Document Format
Description:
Research article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Department of Clinical Phamacology